On August 26, 2022, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") announced that it has formally submitted an IND application for ESG206 to the Center for Drug Evaluation (CDE) and received formal acceptance, with the acceptance number CXSL2200408.

On June 2, 2022, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") announced that it has formally submitted a First-in-Human (FIH) clinical trial application for ESG206 to the Bellberry Human Research Ethics Committee (Bellberry HREC) in Australia, for the treatment of malignant B cell lymphoma and chronic lymphocytic leukemia.